Past Event
日にち
January 15-17,2021
Location
Virtual
2021 Gastrointestinal Cancers Symposium
ポスター
On demand 01/15 - 01/17
Exposure-response (E-R) efficacy and safety (E-S) analyses of tremelimumab as monotherapy or in combination with durvalumab in patients (pts) with unresectable hepatocellular carcinoma (uHCC) - Abstract 313
Co-Authors: Rajesh Krishna, Michelle Green | Rajesh Krishna, Sr. Director, COS-IDD, Michelle Green, Executive Director, COS-IDD
Exposure-response (E-R) efficacy and safety (E-S) analyses of tremelimumab as monotherapy or in combination with durvalumab in patients (pts) with unresectable hepatocellular carcinoma (uHCC) - Abstract 313
